News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nuvilex Release: Human Clinical Trials Using Medical Marijuana Could be Close in the U.S.


4/16/2013 10:27:47 AM

NEW YORK, NY--(Marketwired - April 16, 2013) - With more and more acceptance of medical marijuana here in the U.S., companies like Nuvilex, Inc. (OTCQB: NVLX), and research centers like the California Pacific Medical Center in San Francisco are pleased to see momentum building and opinions changing. As Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., lays the groundwork to begin studying different forms of cancer, it may very well be work like that done by doctors at California Pacific Medical Center that helps lay the groundwork for the industry to conduct human clinical trials.

The use of marijuana for medicinal purposes by those patients suffering from cancer is nothing new. However, the dramatic shift in opinion toward the drug in this country is new. As we've reported before, a recent Pew Research Center poll showed for the first time in 44 years of polling on the topic, that a majority of Americans were in favor of legalizing marijuana. This new shift could very well put pressure on those in Washington, D.C. and the remaining states that have not passed legislation legalizing marijuana or at the very least the compounds found in the drug that may prove vital to cancer research.

First in line at a shot at human clinical trials, could very well be a number of researchers at California Pacific Medical Center. Much like Nuvilex's subsidiary, they will initially utilize cannabidiol (CBD) as the basis for developing treatments for some of the deadliest forms of cancer. The group of doctors at California Pacific Medical Center has been working for more than five years studying cannabidiol which is one of the compounds found in Cannabis. CBD is non-toxic and unlike THC, it is not psychoactive which could very well gain it favor among the drug's detractors.

Two of the researchers involved in the study using CBD, Sean McAllister, Ph.D., and Pierre Desprez, Ph.D., both believe their work is ready for human trials, using the compound to treat metastatic cancer.

Continue reading this article at www.stockhousegroup.com/features

About Stock House Group

Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. We offer a platform to CEOs to develop their story through articles, Research Reports, and CEO Interviews. Additionally, we're building a library for Investors to research small and large cap stocks.


Contact:
Stock House Group
www.stockhousegroup.com
Email Contact
646-397-4020

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com

comments powered by Disqus
Nuvilex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES